Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin

Pharmacotherapy

Volumn 25, Issue 2, 2005, Pages 157-164

  Arpino, Paul A ^a   Demirjian, Zareh ^a   Van Cott, Elizabeth M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Argatroban; Chromogenic factor X; INR; International normalized ratio; Warfarin

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 10; CHROMOGENIC SUBSTRATE; WARFARIN;

ACCURACY; AGED; ANTICOAGULATION; ARTICLE; ASSAY; CONFIDENCE INTERVAL; DATA ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TIME SERIES ANALYSIS; UNIVERSITY HOSPITAL;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; CHROMOGENIC COMPOUNDS; FACTOR X; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; WARFARIN;

EID: 13544255500     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.2.157.56950     Document Type: Article

References (16)

1. Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 1999;36:7-11.
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenisis, frequency, avoidance and management. Drug Saf 1997;17:325-41.
3. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
4. Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematol 1999;36:17-21.
5. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001;103:1479-84.
6. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:638-48.
7. GlaxoSmithKline. Argatroban (argatroban) product information. Research Triangle Park, NC, 2003.
8. Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999;25:61-6.
9. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004;121:593-9.
10. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435-40.
11. Hoppensteadt DA, Kahn S, Fareed J. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs. Clin Chem 1997;43:1786-8.
12. Ciavarella N, Coccheri S, Gensini GF, et al. Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. Thromb Res 1980;19:493-502.
13. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-85.
14. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 suppl):S8-21.
15. Ansell J, Hirsh J, Dalen JE, et al. Managing oral anticoagulant therapy. Chest 2001;119(1 suppl):S22-38.
16. Hyers TM, Angelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(1 suppl):S176-93.